Due to the limited pharmacokinetic and pharmacodynamic characteristics of standard insulins, which frequently result in hypoglycemia as glycosylated hemoglobin levels approach the normal range, there has been renewed interest in developing safer insulin formulations that more closely mimic the basal and mealtime components of endogenous insulin secretion. The gene discussed is INS; the disease is Hypoglycemia.